Live feed08:00:00·32dPRReleasevia QuantisnowInhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 MonotherapyByQuantisnow·Wall Street's wire, on your screen.INBX· Inhibrx Biosciences Inc.Health Care
